26 results about "CD22" patented technology

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and / or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and / or CD19, methods of making a cell comprising the same and vectors encoding the same.

This invention discloses an immune cell that secretes type 2 cytokines under hypoxic conditions and its applications, belonging to the fields of genetic engineering and cell engineering. The invention first constructs a nucleotide fragment encoding hypoxia-induced type 2 cytokines, including a signal peptide gene sequence, a CAR molecule nucleotide sequence targeting CD19 and CD22, and an IL-4 or IL-10 nucleotide sequence containing multiple HRE motifs of a hypoxia-inducible promoter. This nucleotide fragment is delivered to immune cells for stable expression, yielding an immune cell that secretes type 2 cytokines under hypoxic conditions. This immune cell secretes IL-4 or IL-10 only under hypoxic conditions, thereby leveraging the metabolic reprogramming effect of IL-4 or IL-10 on immune cells to enhance their activity under hypoxic conditions, thus achieving better long-term anti-tumor effects.

Provided is a bispecific chimeric antigen receptor targeting CD19 and CD22, which comprises extracellular antigen binding domains of heavy-chain variable regions and light-chain variable regions of anti-CD19 and anti-CD22 antibodies. Further provided is a bispecific CAR-T cell targeting CD19 and CD22.

The present disclosure relates to CD19 / 22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.

The application belongs to the technical field of cell engineering, and particularly relates to a bispecific antibody targeting CD22 and CD19, a chimeric antigen receptor thereof and application. In the bispecific antibody, a CD22 light chain and a CD22 heavy chain are connected through a linker 4 to form a CD22 single-chain antibody, and a CD19 light chain and a CD19 heavy chain are connected through a linker 4 to form a CD19 single-chain antibody, which comprises one of the following structures: (1) the CD22 single-chain antibody and the CD19 single-chain antibody are connected through a linker 1 or a liner 2; (2) the two ends of the CD19 single-chain antibody are connected with the CD22 light chain and the CD22 heavy chain through a linker 3, respectively. The chimeric antigen receptor provided by the application can simultaneously target two different tumor antigens, improve the killing of tumor cells, reduce the probability of immune escape, and reduce the tumor recurrence rate after CAR-T treatment.

Chimeric antigen receptors containing CD19 / CD22 or CD22 / CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

The application belongs to the technical field of biological medicine, and particularly relates to an anti-CD22 nanobody and a preparation method and application thereof. The anti-CD22 nanobody comprises a framework region and a complementarity determining region, wherein the complementarity determining region comprises CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2) and CDR3 (SEQ ID NO: 3). The preparation method comprises the following steps: immunizing a llama with a Human CD22 / His protein, extracting RNA from PBMC cells and reverse transcribing the RNA into cDNA, constructing a phage display library, obtaining a positive clone through CD22 antigen protein panning after sequencing analysis, and expressing the antibody through a mammalian cell expression system. The application adopts an optimized phage display technology, has a short screening cycle, and the obtained nanobody has a small molecular weight, a stable structure and high affinity to CD22. The antibody can be efficiently expressed through a mammalian cell, and retains natural modification activity.

The present disclosure relates to an antibody binding to CD22, a bispecific antibody including the same, a chimeric antigen receptor, an antibody-drug conjugate, and uses thereof. According to one aspect, effective anticancer effects can be provided even for patients who are refractory to CD19-targeted therapies. Further, when using CD22 CAR NK cells or bispecific CD22 / CD19 CAR NK cells, significantly enhanced reduction of cancer cells can be achieved.

The present invention provides a bispecific chimeric antigen receptor that targets CD19 and CD22, which comprises an extracellular antigen-binding domain comprising the heavy chain variable region and the light chain variable region of an anti-CD19 antibody and an anti-CD22 antibody.The present invention further provides a bispecific CAR-T cell that targets CD19 and CD22.

The present disclosure provides multispecific anti-CD22 / anti-4-1BB antigen-binding molecules comprising a first antigen-binding domain that binds specifically to CD22 and a second antigen-binding domain that binds specifically to 4-1 BB. In certain embodiments, the molecules further comprise a third antigen-binding domain that binds 4-1 BB. In certain embodiments, the molecules are multispecific antibodies or antigen-binding fragments thereof. In certain embodiments, the antibodies are useful in treating a CD22-associated disease or disorder (e.g., lymphoma).

The present invention provides a cell that co-expresses a first chimeric antigen receptor (CAR) and a second CAR on the surface of the cell, each CAR comprising an antigen binding domain wherein the antigen binding domain of the first CAR binds CD19 and the antigen binding domain of the second CAR binds CD22.

The present application relates to the use of an Axl agonist, a Mertk agonist, a CCR5 inhibitor or a CD22 inhibitor in the prevention or treatment of severe acute pancreatitis (SAP).

The present disclosure provides multispecific anti-CD22 / anti-4-1BB antigen-binding molecules comprising a first antigen-binding domain that binds specifically to CD22 and a second antigen-binding domain that binds specifically to 4-1BB. In certain embodiments, the molecules further comprise a third antigen-binding domain that binds 4-1BB. In certain embodiments, the molecules are multispecific antibodies or antigen-binding fragments thereof. In certain embodiments, the antibodies are useful in treating a CD22-associated disease or disorder (e.g., lymphoma).

The present disclosure relates to CD22 binding molecules, such as anti-CD22 antibodies, for the treatment of cancer, and related antibody-drug conjugates.

The present invention relates to a reagent panels for the measurement of minimal residual disease (MRD) associated with pediatric B-cell precursor acute lymphoblastic leukemia (B- ALL) by multiparametric flow cytometry. The reagent panel of the invention comprises a combination of antibodies directed against markers, wherein the combination of antibodies comprises i) antibodies targeting markers CD45, CD20, CD34, CD38, CD10, CD58, CD66c, CD73, CD81, CD123, CD304, CD44, CD86, CD99 and CD371, and ii) antibodies targeting markers CD19 and / or CD22, wherein the antibodies are conjugated with fluorochromes. The invention further relates to the use of said panels for detecting MRD associated with B-ALL and / or for identifying a subject at risk of developing B-ALL relapse. The invention also relates to methods of detecting MRD associated with B-ALL. Key advantages of the invention include achieving high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity.

The application relates to preparation and application of anti-CD22 rabbit recombinant monoclonal antibodies. The obtained antibodies have good specificity, and most importantly, the antibodies have high affinity and can recognize natural cell surface CD22 proteins, and can be used for flow and ELISA detection applications.

Provided are a multispecific antigen-binding molecule, a chimeric antigen receptor comprising same, a cell expressing the described chimeric antigen receptor, and use thereof. The multispecific antigen-binding molecule comprises a multispecific antibody. The multispecific antibody comprises: a first functional region targeting CD19, a second functional region targeting CD22, and a third functional region targeting BCMA, wherein the first functional region is an anti-CD19 heavy-chain antibody or an antigen-binding fragment thereof, the second functional region is an anti-CD22 heavy-chain antibody or an antigen-binding fragment thereof, and the third functional region is an anti-BCMA heavy-chain antibody or an antigen-binding fragment thereof. The described multispecific antibody has a ligand-binding ability and a cell-binding ability.

The application discloses a kind of chimeric antigen receptor macrophages and preparation method thereof.To the problem that traditional T cell costimulatory domain is not matched with macrophage signal pathway, the application provides a CAR structure specially designed for the biological characteristics of macrophage.The chimeric antigen receptor expressed by the CAR-M cell includes at least one costimulatory domain selected from Ncr1, TLR5, Rage and Tim4, and the CAR structure is composed of CD22 scFv extracellular antigen recognition region, CD8 alpha hinge region, transmembrane region, the costimulatory domain and CD3 zeta intracellular signal domain in sequence.By constructing the recombinant expression plasmid of pB vector skeleton and inserting P2A-EGFP expression monitoring element, RAW264.7 macrophages are transfected by using Zeta life transfection reagent, and the CAR positive rate can reach more than 97% by flow cytometry or confocal microscopy verification.The application realizes the efficient activation of phagocytosis, antigen presentation and microenvironment remodeling functions specific to macrophages, and significantly improves the application potential of CAR-M in solid tumor treatment.

This invention provides a therapy for treating CD22-positive cancers such as B-cell acute lymphoblastic leukemia (B-ALL). Specifically, this invention provides an anti-CD22 monoclonal antibody for treating CD22-positive cancers, whose scFv, as part of a chimeric antigen receptor (CAR) T cell, can target the first Ig extracellular domain (i.e., the domain furthest from the membrane) of the CD22 antigen.

The present invention provides bispecific antigen binding molecules and uses thereof. The bispecific antigen binding molecule comprises a bispecific antibody or an antigen binding fragment thereof, the bispecific antibody comprises a first functional area targeting CD19 and a second functional area targeting CD22, the first functional area is an anti-CD19 heavy-chain antibody or an antigen binding fragment thereof, and the second functional area is an anti-CD22 heavy-chain antibody or an antigen binding fragment thereof. And the second functional region is an anti-CD22 heavy chain antibody or an antigen binding fragment thereof. The bispecific antibodies herein have significant ligand binding capacity and cell binding capacity.

To provide an isolated nucleic acid molecule encoding a CD19 / CD22 tandem chimeric antigen receptor, and pharmaceutical compositions and therapeutic methods applicable for treating cancer in a subject.SOLUTION: In one embodiment, an isolated nucleic acid molecule is provided that encodes a CD19 / CD22 tandem chimeric antigen receptor that includes at least one extracellular antigen-binding domain including a CD19 / CD22 antigen-binding domain, at least one transmembrane domain, and at least one intracellular signaling domain, where the CD19 / CD22 tandem chimeric antigen receptor is encoded by a specific nucleotide sequence.SELECTED DRAWING: Figure 1A

This invention belongs to the field of immunology and relates to a single-domain antibody against CD22 and its uses. The single-domain antibody is composed of heavy chains, including heavy chain CDR1 shown in any one of SEQ ID NO:30-SEQ ID NO:34, heavy chain CDR2 shown in any one of SEQ ID NO:35-SEQ ID NO:39, and heavy chain CDR3 shown in any one of SEQ ID NO:40-SEQ ID NO:43. Compared with the prior art, the beneficial effects of this invention are: this invention uses bioengineering technology to screen for single-domain antibodies specifically targeting CD22, exhibiting good antibody affinity.

Chimeric antigen receptors containing CD19 / CD22 or CD22 / CD19 antigen-binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen-binding fragments, and pharmaceutical compositions related to the chimeric antigen receptors are also disclosed. Methods for treating or preventing cancer in a subject and methods for generating chimeric antigen receptor T cells are also disclosed.

A composition comprising a complex containing a polynucleotide of interest and a carrier is provided. The surface of the complex is coated covalently or non-covalently with a CD22 receptor ligand and can target CD22 on cells. The carrier may contain a polymer, a lipid, or a protein. The polynucleotide of interest may contain, for example, plasmid DNA (pDNA), linear double stranded DNA (dsDNA), linear single stranded DNA (ssDNA), messenger RNA (mRNA), small hairpin RNA (shRNA), or small interfering RNA (siRNA) that alters level or activity of a target molecule in B cells. Methods of delivering a polynucleotide of interest to a CD22 expressing cell, and methods of treating a B cell-associated disease (such as acute lymphoblastic leukemia) in a subject using the composition are also provided.